KR20170123439A - The method for manufacturing a juice containing jerusalem artichoke and bitter melon, and juice manufactured by the method - Google Patents
The method for manufacturing a juice containing jerusalem artichoke and bitter melon, and juice manufactured by the method Download PDFInfo
- Publication number
- KR20170123439A KR20170123439A KR1020160052735A KR20160052735A KR20170123439A KR 20170123439 A KR20170123439 A KR 20170123439A KR 1020160052735 A KR1020160052735 A KR 1020160052735A KR 20160052735 A KR20160052735 A KR 20160052735A KR 20170123439 A KR20170123439 A KR 20170123439A
- Authority
- KR
- South Korea
- Prior art keywords
- juice
- momordica charantia
- present
- potato
- diabetes
- Prior art date
Links
- 235000011389 fruit/vegetable juice Nutrition 0.000 title claims abstract description 61
- 244000302512 Momordica charantia Species 0.000 title abstract description 11
- 235000009811 Momordica charantia Nutrition 0.000 title abstract description 11
- 238000000034 method Methods 0.000 title abstract description 9
- 240000008892 Helianthus tuberosus Species 0.000 title abstract description 7
- 235000003230 Helianthus tuberosus Nutrition 0.000 title abstract description 7
- 238000004519 manufacturing process Methods 0.000 title abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000005406 washing Methods 0.000 claims abstract description 4
- 244000061456 Solanum tuberosum Species 0.000 claims description 67
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 65
- 235000015277 pork Nutrition 0.000 claims description 24
- 235000012015 potatoes Nutrition 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 244000068485 Convallaria majalis Species 0.000 claims description 3
- 235000009046 Convallaria majalis Nutrition 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 abstract description 26
- 239000008280 blood Substances 0.000 abstract description 26
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 21
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 14
- 239000008103 glucose Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 13
- 230000003914 insulin secretion Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 238000001035 drying Methods 0.000 abstract description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract description 2
- 239000002075 main ingredient Substances 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 35
- 102000004877 Insulin Human genes 0.000 description 17
- 108090001061 Insulin Proteins 0.000 description 17
- 229940125396 insulin Drugs 0.000 description 17
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 16
- 229960001052 streptozocin Drugs 0.000 description 14
- 235000013361 beverage Nutrition 0.000 description 10
- 230000010030 glucose lowering effect Effects 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 244000269722 Thea sinensis Species 0.000 description 6
- 235000021395 porridge Nutrition 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 244000017020 Ipomoea batatas Species 0.000 description 3
- 235000002678 Ipomoea batatas Nutrition 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- YSINCDVRUMTOPK-UHFFFAOYSA-N 5-o-methylgenistein Chemical compound O=C1C=2C(OC)=CC(O)=CC=2OC=C1C1=CC=C(O)C=C1 YSINCDVRUMTOPK-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 241000219104 Cucurbitaceae Species 0.000 description 2
- 244000097654 Cudrania tricuspidata Species 0.000 description 2
- 235000010918 Cudrania tricuspidata Nutrition 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229930185803 charantin Natural products 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 235000020418 red date juice Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241000332371 Abutilon x hybridum Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 244000302544 Luffa aegyptiaca Species 0.000 description 1
- 235000009814 Luffa aegyptiaca Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- IHPVFYLOGNNZLA-UHFFFAOYSA-N Phytoalexin Natural products COC1=CC=CC=C1C1OC(C=C2C(OCO2)=C2OC)=C2C(=O)C1 IHPVFYLOGNNZLA-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241001417494 Sciaenidae Species 0.000 description 1
- PBWOIPCULUXTNY-UHFFFAOYSA-N Sitosterylacetat Natural products C1C=C2CC(OC(C)=O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 PBWOIPCULUXTNY-UHFFFAOYSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 235000020379 cucumber juice Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000667 effect on insulin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000012528 insulin ELISA Methods 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 229940125395 oral insulin Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000280 phytoalexin Substances 0.000 description 1
- 150000001857 phytoalexin derivatives Chemical class 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008262 pumice Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
- A23L2/04—Extraction of juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Preparation Of Fruits And Vegetables (AREA)
Abstract
Description
본 발명은 혈당강하 및 인슐린분비를 촉진함으로써 당뇨병을 개선하는 효과가 우수한 생돼지감자 및 여주를 주원료로 하는 돼지감자여주즙을 제조하는 방법에 관한 것이다.The present invention relates to a method for preparing a porcine potato juice which is mainly used as raw pork potatoes and yeast, which is excellent in improving diabetes by promoting blood glucose lowering and insulin secretion.
구체적으로, 성숙한 생돼지감자 1kg을 깨끗이 씻어 물기를 제거하는 단계:Specifically, 1 kg of mature raw pork potato is cleanly washed to remove water:
미성숙한 초록색의 여주열매(생여주) 1kg을 깨끗이 씻고 얇게 썰어 50~60℃에서 6~8시간 건조하여 생여주 1000g당 95~105g의 건조여주를 얻는단계; 및1kg of immature green lily of the valley (lye) is cleanly washed, thinly sliced and dried at 50 ~ 60 ° C for 6 ~ 8 hours to obtain 95 ~ 105g of dry lye per 1000g of lard; And
생돼지감자 1000g당 건조여주 2.5g을 혼합하여 소량의 물을 가하고 고압으로 105~115℃에서 2~3시간 처리하는 단계를 포함하는 돼지감자여주즙 제조방법에 관한 것이다.The present invention relates to a method for preparing a potato safflower juice comprising the steps of mixing 2.5 g of dried prawn per 1000 g of raw potatoes, adding a small amount of water, and treating the mixture at 105 to 115 캜 for 2 to 3 hours under high pressure.
당뇨병(diabetes mellitus)은 췌장의 베타세포에서 분비되는 인슐린이 부족하거나 그 기능을 제대로 발휘하지 못하여 체내에서 포도당이 에너지원으로 이용되지 못하고 혈액 내에 고농도로 남아 있다가 소변으로 배설되는 질환이다. 그러나 이러한 현상들은 당뇨병 발명 초기에 나타나는 급성 증상에 불과하며, 만성이 될 경우, 이로 인하여 혈액순환 장애, 만성 피로, 고혈압, 심근경색, 당뇨병성 신경병증, 망막병증(시력장애, 실명, 망막출혈) 및 백내장 등의 합병증을 유발하며, 인체의 전반적인 대사 기능 및 감각 기능이 저하되어 치명적인 결과를 가져온다.Diabetes mellitus is a disease in which glucose is not used as an energy source in the body due to insufficient secretion of insulin secreted from the pancreatic beta cells or its function, and it remains in high concentration in the blood and excreted in the urine. However, these phenomena are only acute symptoms that appear early in the invention of diabetes, and when they become chronic, they cause blood circulation disorder, chronic fatigue, hypertension, myocardial infarction, diabetic neuropathy, retinopathy (visual disturbance, blindness, And cataracts, resulting in fatal consequences due to reduced overall metabolic and sensory functions of the human body.
당뇨병은 그 유형에 따라 몇 가지로 분류되는데, 첫 번째로 인슐린 의존성 또는 소아 당뇨병이라고도 불리는 제1형 당뇨병은 자가면역질환으로 발생하는 당뇨병이다. 즉, 외부로부터의 감염과 싸워야 할 우리 몸의 면역체계가 췌장에서 인슐린을 분비하는 베타세포를 공격하여 파괴시켜 인슐린이 전혀 분비되지 않거나 분비가 저하되어 발생하는데, 우리 몸의 면역체계가 베타세포를 어떤 기작을 통해 공격하는지 아직까지 그 원인이 밝혀지지 않고 있다. 또한, 제1형 당뇨병은 전체 당뇨병의 10% 미만을 차지하며 주로 어린이와 청장년에서 주로 발생하지만 모든 연령에서 발생할 수 있으며, 그 증상은 갈증, 배뇨량 증가, 계속되는 허기, 체중감소, 시력 감퇴, 극도의 피로감 등이 있고 이를 치료하지 않으면 생명을 위협하는 혼수에 빠질 수도 있다. Diabetes is classified into several types according to its type. First,
두 번째로는 인슐린 비의존성 당뇨병이라고도 불리는 제2형 당뇨병이 있다. 이는 전체 당뇨병의 90% 이상을 차지하고 주로 40세 이후에 나타나며 대개 환자가 비만이다. 제2형 당뇨병의 경우 췌장이 인슐린을 분비하지만 우리 몸이 분비된 인슐린을 효과적으로 활용하지 못하여 혈당이 높아지게 되는 경우로, 경구 혈당강하제 및 인슐린으로 치료한다. 제2형 당뇨병은 증상이 서서히 나타나고 제1형 당뇨병의 증상만큼 뚜렷하지 않은데, 증상으로는 피로, 잦은 배뇨, 갈증, 체중감소, 시력 감퇴, 잦은 감염, 상처가 잘 아물지 않는 것 등이 있다. 세 번째로는 임신 중에 새로이 발생하거나 임신 중에 처음으로 진단받은 당뇨병을 말하는 임신성 당뇨병이 있는데, 이는 일반적으로 출산 등으로 임신이 종료되면 사라지지만 나중에 제2형 당뇨병이 발생할 위험성이 높다. Second, there is
마지막으로는 기타요인에 의한 당뇨병으로 분류되는데, 이는 특정 약물, 호르몬, 유전 질환 등으로 인슐린 활동이 저하되어 나타나는 당뇨병을 말하며, 췌장염 혹은 췌장암으로 인한 당뇨병도 여기에 포함된다.Finally, it is classified as diabetes due to other factors, which refers to diabetes caused by a decrease in insulin activity due to specific drugs, hormones, genetic diseases, etc., and diabetes caused by pancreatitis or pancreatic cancer.
한편, 당뇨병 치료에 있어서 궁극적인 목적은 혈당을 정상적으로 유지하도록 관리하면서 합병증을 예방하는데 있다고 할 수 있다. 당뇨병 환자의 건강관리법은 크게 식이요법, 운동요법, 약물요법의 3가지로 나눌 수 있다.On the other hand, the ultimate goal in the treatment of diabetes is to prevent complications by managing to maintain normal blood glucose. The health care method of diabetic patients can be roughly classified into three kinds of diet, exercise therapy, and drug therapy.
그러나 현재 당뇨병 치료를 위해 사용되고 있는 약물의 경우, 지속적인 약효가 미비하고 체내에서 각종 부작용을 일으키는 문제점이 있으며 특히 많은 치료제들이 신장독성 및 간독성을 유발시키는 문제점이 있다.However, in the case of the drugs currently used for the treatment of diabetes, there is a problem in that there is insufficient continuous effect and various side effects are caused in the body, and in particular, many therapeutic agents cause kidney toxicity and hepatotoxicity.
이에 본 발명자는 돼지감자 및 여주가 혈당강하 및 당뇨병을 개선 또는 치료할 수 있음을 확인하였고, 나아가 소비자가 쉽고 편리하게 돼지감자 및 여주를 이용한 음료, 차 및 죽을 섭취할 수 있는 조성물을 제공함으로써 본 발명을 완성하였다.Accordingly, the present inventors have confirmed that pig potatoes and sweet potatoes can improve or treat hypoglycemia and diabetes, and further provide a composition for consumers to ingest beverages, tea and porridge using pig potatoes and sweet potatoes easily and conveniently, .
이하에서, 본 발명에 사용된 돼지감자 및 여주에 대해 간략히 서술한다.Hereinafter, pig potatoes and sweet potatoes used in the present invention will be briefly described.
돼지감자(영문명: Jerusalem artichoke, 학명: Helianthus tuberosus, 일명: 뚱딴지)는 북아메리카가 원산지인 국화과의 다년생 식물로 8~9월에 해바라기처럼 꽃을 피우고, 꽃이 지는 10월 말경, 즉 외부 온도가 17℃도 이하가 되면 땅속에 감자모양의 뿌리열매가 생기는데 이 뿌리를 돼지감자라고 한다. 돼지감자의 주성분은 프럭토스(fructose) 중합체인 이눌린(inulin)으로 췌장에서 발생하는 호르몬인 글루카곤이 간장에 저장된 글리코겐을 포도당으로 분해하는 것을 억제하여 혈당을 안정화시키고, 당뇨 합병증의 원인인 당화혈색소(HbA1c)의 수치를 낮추는 역할을 한다.Helianthus tuberosus is a perennial plant of Asteraceae that originated in North America. It blooms like a sunflower in August-September, and at the end of October when the flower is in the air, that is, when the outside temperature is 17 When the temperature is below ℃, potato-shaped root fruit is formed in the ground. This root is called a potato potato. The main ingredient of the potatoes is inulin which is a fructose polymer. Glucagon, which is a hormone in the pancreas, stabilizes blood sugar by inhibiting decomposition of glycogen stored in the liver into glucose, HbA1c).
여주(Bitter gourd)는 박과(Cucurbitaceae)에 속하는 채소 또는 약용식물로 주로 열대나 아열대 지역에서 자란다. 주로 열매를 식용으로 이용하는데, 쓴맛이 강하여 일반적으로 영문으로는 bitter gourd 또는 bitter melon이라고 한다. 여주의 주성분은 펩타이드성 물질인 카란틴(charantin)으로 베타세포를 활성화시켜 인슐린 분비를 촉진함으로써 혈당을 낮춰주는 역할을 한다.Bitter gourd is a vegetable or medicinal plant belonging to the genus Cucurbitaceae and mainly grows in tropical or sub-tropical regions. It is mainly used for food, but bitter taste is strong, so it is commonly called bitter gourd or bitter melon in English. The major component of Yeoju is the peptide, charantin, which activates the beta cells and promotes insulin secretion, thereby lowering blood sugar.
선행특허문헌을 살펴보면, 등록특허공보 제10-1312491호 "혈당강하용 기능성 여주음료의 제조방법"에는 여주를 주원료로 하여 흑설탕 또는 물과 1:1의 비율로 혼합하여 여주 발효액 또는 여주 중탕액을 만들고 여기에 돼지감자추출물, 흑삼추출물, 뽕잎추출물 및 도라지추출물을 혼합하여 기능성 음료를 제공한다고 기재하였기에 본 발명의 조성물과 상이하다. 또한, 등록특허공보 제10-1320604호 "여주즙 제조방법 및 그 방법으로 제조된 여주즙"에는 미성숙여주와 돼지감자를 건조, 가열 및 여과공정을 거쳐 여주즙을 제조하여 혈당을 안정시키고 인슐린분비를 촉진한다고 하였지만, 이와 관련된 실험방법 및 효과를 기재하고 있지 않다.In reference to the prior patent documents, Japanese Patent Application No. 10-1312491 entitled " Method for manufacturing a functional low-fat drink for blood glucose lowering ", mixed with brown sugar or water at a ratio of 1: 1, And it is described that a functional beverage is prepared by mixing pig potato extract, black ginseng extract, mulberry leaf extract and bellflower extract, and thus is different from the composition of the present invention. In addition, in JP-A No. 10-1320604 entitled " Yeast juice manufacturing method and Yeoju juice prepared by the method ", stable juice is prepared by drying, heating and filtering the immature Yeoju and porcine potatoes to stabilize blood glucose, But does not describe the experimental methods and effects associated therewith.
본 발명의 해결과제는, 혈당강하 및 인슐린분비를 촉진함으로써 당뇨병을 개선하는 효과가 우수한 생돼지감자 및 여주를 주원료로 하는 돼지감자여주즙을 제공하는 것이다.A solution to the problem of the present invention is to provide a raw porcine potato having excellent effects of improving diabetes by promoting blood glucose lowering and insulin secretion, and a porcine potato juice containing as a main raw material.
본 발명의 해결과제는 돼지감자여주즙을 이용한 음료, 차 및 죽과 같은 식품조성물을 제공하는 것이다.A solution to the problem of the present invention is to provide a food composition such as beverage, tea and porridge using potato juice.
본 발명은,According to the present invention,
성숙한 생돼지감자 1kg을 깨끗이 씻어 물기를 제거하는 단계:Washing 1kg of mature raw pork potatoes to remove the moisture:
미성숙한 초록색의 여주열매(생여주) 1kg을 깨끗이 씻고 얇게 썰어 50~60℃에서 6~8시간 건조하여 생여주 1000g당 95~105g의 건조여주를 얻는단계; 및1kg of immature green lily of the valley (lye) is cleanly washed, thinly sliced and dried at 50 ~ 60 ° C for 6 ~ 8 hours to obtain 95 ~ 105g of dry lye per 1000g of lard; And
생돼지감자 1000g당 건조여주 2.5g을 혼합하여 소량의 물을 가하고 고압으로 105~115℃에서 2~3시간 처리하는 단계를 포함하는 돼지감자여주즙 제조방법을 제공함으로써,And 2.5 g of dry pumice per 1000 g of raw pork potato are mixed, and a small amount of water is added thereto, followed by treatment at 105 to 115 ° C for 2 to 3 hours at a high pressure.
해결과제를 해결하고자 한다.To solve the problem.
본 발명의 효과는, 혈당강하 및 인슐린분비를 촉진함으로써 당뇨병을 개선하는 효과가 우수한 생돼지감자 및 여주를 주원료로 하는 돼지감자여주즙을 제공할 수 있다.The effect of the present invention is to provide a raw porcine potato having excellent effects of improving diabetes by promoting blood glucose lowering and insulin secretion, and a porcine potato juice containing as a main raw material.
본 발명의 효과는, 돼지감자여주즙을 이용한 음료, 차 및 죽과 같은 식품조성물을 제공하는 것이다.The effect of the present invention is to provide a food composition such as beverage, tea and porridge using potato juice.
도 1은 돼지감자여주즙이 혈당강하에 미치는 효과를 측정한 결과를 나타낸 것이다.
도 2는 돼지감자여주즙이 인슐린에 미치는 효과를 측정한 결과를 나타낸 것이다.Fig. 1 shows the results of measuring the effect of the porcine potato juice extract on blood glucose level.
Fig. 2 shows the results of measuring the effect of porcine potato juice on insulin.
본 명세서 및 청구범위에 사용된 용어나 단어는 통상적이거나 사전적인 의미로 한정해서 해석되어서는 안 되며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다.The terms and words used in the present specification and claims should not be construed as limited to ordinary or dictionary terms and the inventor may properly define the concept of the term in order to best describe its invention It should be construed as meaning and concept consistent with the technical idea of the present invention.
따라서 본 명세서에 기재된 실험예와 참고예는 본 발명의 가장 바람직한 일실시예에 불과한 뿐이고 본 발명의 기술적 사상을 모두 대변하는 것은 아니므로, 본 출원시점에 있어서 이들을 대체할 수 있는 다양한 균등물과 변형예들이 있을 수 있음을 이해하여야 한다.Therefore, the experimental examples and the reference examples described in the present specification are merely the most preferred embodiments of the present invention and are not intended to represent all of the technical ideas of the present invention. Therefore, various equivalents and variations Examples should be understood.
이하, 도면을 참조하여 설명하기에 앞서, 본 발명의 요지를 드러내기 위해서 필요하지 않은 사항 즉 통상의 지식을 가진 당업자가 자명하게 부가할 수 있는 공지 구성에 대해서는 도시하지 않거나, 구체적으로 기술하지 않았음을 밝혀둔다.Before describing the present invention with reference to the accompanying drawings, it should be noted that the present invention is not described or specifically described with respect to a known configuration that can be easily added by a person skilled in the art, Let the sound be revealed.
실시예Example 1. 돼지감자 및 여주를 이용한 1. Using potatoes and potatoes 돼지감자여주즙Pork potato juice 제조방법 Manufacturing method
1. 성숙한 생돼지감자 1kg을 깨끗이 씻어 물기를 제거한다.1. Wash 1 kg of mature raw pork potatoes to remove water.
2. 여주는 미성숙한 초록색의 여주열매(생여주) 1kg을 깨끗이 씻고 얇게 썰어 50~60℃에서 6~8시간 건조하여 생여주 1000g당 95~105g의 건조여주를 얻었다.2. Yeoju was washed with 1kg of immature green berries (lye), sliced thinly and dried at 50 ~ 60 ℃ for 6 ~ 8 hours to obtain 95 ~ 105g dry leaves per 1,000g of raw leaves.
이와 같이 미성숙 여주를 사용하는 이유는 미성숙 여주에 식물인슐린(p-insulin), 카라틴(charantin) 및 비타민C 등의 유용한 성분이 많이 함유되어 있기 때문이다.The reason for using immature rats is that immature rats contain many useful components such as plant insulin (p-insulin), charantin, and vitamin C.
또한, 여주를 건조시키는 이유는 여주의 영양소 파괴를 방지하고 쓴맛을 제거하기 위한것이다.Also, the reason for drying Yeoju is to prevent the destruction of Yeoju's nutrients and to eliminate the bitter taste.
3. 생돼지감자 1000g당 건조여주 2.5g, 5.0g, 7.5g, 10.0g을 각각 혼합하여 소량의 물을 가하고 고압으로 105~115℃에서 2~3시간 처리하여 돼지감자여주즙을 얻었다.3. Pork potato juice was obtained by mixing 2.5 g, 5.0 g, 7.5 g, and 10.0 g of dried porridge per 1000 g of raw potatoes, adding a small amount of water, and treating it at 105 to 115 ° C for 2 to 3 hours under high pressure.
상기 돼지감자여주즙의 영양성분 결과는 표 1과 같다.Table 1 shows the nutritional composition results of the potato juice.
참조예Reference Example 1. One. 돼지감자여주즙의Pork potato juice 관능평가 Sensory evaluation
상기 기재된 실시예 1에서 생돼지감자와 생여주를 혼합하고 소량의 물을 가하여 고압처리단계를 거쳐 제조한 돼지감자여주즙을 20~30대의 남녀 10명에게 돼지감자여주즙의 맛과 향 및 기호도에 관한 평가를 실시하였다. In the above-described Example 1, a mixture of raw potato and raw potato was mixed with a small amount of water and subjected to a high-pressure treatment step to prepare 10 potato juice of 20 to 30 years old male and female to taste and aroma of pork potato juice The results were as follows.
평가 결과는 0~5점 척도를 사용하여 평균값으로 나타내었으며, 숫자가 클수록 양호한 것을 의미할 수 있다.The evaluation result is expressed as an average value using a scale of 0 to 5, and the larger the number, the better.
구분
division
상기 표 1에 나타난 바와 같이, 생돼지감자 1000g당 건조여주 2.5g을 혼합한 돼지감자여주즙이 다른 돼지감자여주즙에 비하여 맛, 향, 기호도가 높은 것을 알 수 있다.As shown in Table 1, it can be seen that the taste, flavor, and preference of the porcine potato juice mixed with 2.5 g of the dry porridge per 1000 g of the raw potato potato are higher than those of the other potato juice.
실시예Example 2. 2. 돼지감자여주즙을Pork potato juice 이용한 식품조성물 Used food composition
실시예 1에서 제공한 돼지감자여주즙을 이용하여 식품조성물 및 건강기능식품을 제공한다.A food composition and a health functional food are provided using the porcine potato juice provided in Example 1.
본 발명에 따른 식품 조성물을 이용한 건강기능식품은, 기능성 음료, 각종 식품류, 건강보조식품, 차, 과자류, 껌, 차, 비타민 복합제 등과 같이 다양한 형태로 제공될 수 있다.The health functional food using the food composition according to the present invention may be provided in various forms such as functional beverage, various foods, health supplement, tea, confectionery, gum, tea, and vitamin complex.
본 발명의 조성물은 분말, 과립, 정제, 캡슐 등의 다양한 형태로 제조될 수 있다. The composition of the present invention can be prepared in various forms such as powders, granules, tablets, capsules and the like.
본 발명의 조성물은 염증, 통증 및 가래의 예방 및 개선을 목적으로 식품 또는 음료에 첨가될 수 있다. 이때, 식품 또는 음료 중의 상기 조성물의 양은 일반적으로 본 발명의 건강식품 조성물은 전체 식품 중량의 1 내지 5 중량%로 가할 수 있으며 건강 음료 조성물은 100㎖를 기준으로 0.02 내지 10g, 바람직하게는 0.3 내지 1g의 비율로 가할 수 있다.The composition of the present invention may be added to foods or beverages for the purpose of preventing and improving inflammation, pain and sputum. Here, the amount of the composition in the food or beverage is generally from 1 to 5% by weight of the total food weight of the health food composition of the present invention, and the health beverage composition comprises 0.02 to 10 g, 1 g.
본 발명의 건강 음료 조성물은 지시된 비율의 필수 성분으로서 자초를 함유하는 것 외에 액체성분에는 특별한 제한점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages, in addition to containing the seeds as an essential ingredient in the indicated ratio, and there is no particular limitation to the liquid ingredient.
상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등의 디사카라이드, 예를 들어 말토스, 슈크로스 등의 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리통 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100㎖당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g이다.Examples of the above-mentioned natural carbohydrates include monosaccharides such as disaccharides such as glucose and fructose such as maltose, sucrose and the like and polysaccharides such as dextrin, cyclodextrin and the like Sugar, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 일긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 조성물들은 천연 과일 쥬스 및 채소 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하지는 않으나 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다. In addition to the above, the composition of the present invention can be applied to various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and aging agents (cheese, chocolate etc.), pectic acid and its salts, , Protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the compositions of the present invention may contain flesh for the production of natural fruit juices and vegetable beverages. These components may be used independently or in combination. The proportion of such an additive is not critical but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
실험예Experimental Example 1. One. 돼지감자여주즙이Pork potato juice 혈당강하에 미치는 효과 Effect on blood glucose lowering
(1-1) 실험방법(1-1) Experimental method
1) 실험용 동물은 샘다코에서 공급받은 150~160g의 Sprague-Dawley Rat 5주령을 1주일간 적응시킨 후 실험에 사용하였다. 1) Experimental animals were used for the experiment after adapting 150 ~ 160g of Sprague-Dawley Rat 5 weeks old, which was supplied by Sam Dako, for 1 week.
2) 시료는 상기 실시예 1에서 제조한 돼지감자여주즙을 25%가 되도록 증류수에 희석하여 음료수로 공급하였다. (예비실험에서 돼지감자여주즙 비율이 증류수에 대하여 50% 이상인 경우는 rat이 음수하지 않았으며, 25% 비율의 경우 rat이 체중을 유지하고 혈당저하 효과를 보였고, 15% 이하군에서 혈당저하효과 나타나지 않아 증류수에 대하여 돼지감자여주즙 비율 25%를 선택하였다.)2) Samples were diluted in distilled water to a concentration of 25% of the porcine potato juice prepared in Example 1 and supplied as drinking water. (In the preliminary experiment, rat was not negative when the ratio of porcine potato juice to distilled water was more than 50%. In the case of 25% ratio, the rat maintained the weight and had hypoglycemic effect. For the distilled water, 25% of the pork potato juice ratio was selected.
3) 상기 Rat을 5주 동안 사육(1주는 적응, 4주 동안 실험)하였다.3) The Rats were reared (1 week adaptation, 4 weeks experiment) for 5 weeks.
4) 당뇨유발을 위해 Streptozocin(STZ)을 0.1M 구연산 완충액(pH 4.2)액에 녹여 12시간 절식시킨 후 100mg/체중kg으로 복강주사 하였다. 다음날, 꼬리정맥에서 채혈하여 혈당측정기(Accucheck, Mannaheim. Germany)로 혈당 300mg/dl 이상의 rat를 당뇨유발동물로 선택하여 실험군으로 하였다. 4) Streptozocin (STZ) was dissolved in 0.1M citric acid buffer solution (pH 4.2) for 12 hours to induce diabetes and 100 mg / kg body weight was intraperitoneally injected. The next day, blood was collected from the tail vein and a rat with blood glucose level of 300 mg / dl or more was selected as a diabetic group by using a glucose meter (Accucheck, Mannaheim, Germany).
5) 혈당측정은 1주일 간격으로 꼬리정맥에서 채혈하여 혈당측정기로 측정하였다.5) Blood glucose was collected from the tail vein at intervals of one week and measured with a glucose meter.
(1-2) 실험결과(1-2) Experimental results
실험결과는 표 3 및 첨부된 도 1을 참조한다.The experimental results refer to Table 3 and attached FIG.
division
표 3 및 도 1은 돼지감자여주즙이 혈당강하에 미치는 효과를 측정한 결과를 나타낸 것으로, 혈장 포도당의 수준변화는 정상군은 112.3~113.2mg/dL로 일정하게 유지되는 것에 비해 STZ(STZ대조군), 돼지감자즙(STZ+돼지감자즙군), 돼지감자여주즙(STZ+2.5%돼지감자여주즙), 꾸지뽕즙(STZ+2.5%꾸지뽕)은 1주 후부터 증가하였다.Table 3 and FIG. 1 show the results of measuring the blood glucose lowering effect of porcine potato juice. The level of plasma glucose was constantly maintained at 112.3 ~ 113.2 mg / dL in the normal group, ), Pork potato juice (STZ + pork potato juice), pork potato juice juice (STZ + 2.5% pork potato juice juice) and jujube juice (STZ + 2.5% cucumber juice) increased after one week.
4주 후 STZ는 342.1±6.2mg/dL로, 돼지감자즙은 336.5±22.5mg/dL로, 돼지감자여주즙 273.2±36.9mg/dL로, 꾸지뽕즙은 333.7±22.5mg/dL로 측정되어 모두 1주차에 비해 혈당이 감소 되었지만, 돼지감자여주즙이 STZ, 돼지감자즙 및 꾸지뽕즙에 비해 혈당을 유의적으로 낮추는 것으로 확인되었다.After 4 weeks, the STZ was 342.1 ± 6.2 mg / dL, the potato juice was 336.5 ± 22.5 mg / dL, the potato juice juice was 273.2 ± 36.9 mg / dL and the jujube juice was 333.7 ± 22.5 mg / The blood glucose level was decreased compared with the first week, but the juice of porcine potato juice significantly lowered the blood glucose level compared to the STZ, the potato juice and the croaker juice.
이하에서, 본 발명에서 사용된 꾸지뽕에 대해 간략히 서술한다.Hereinafter, the present invention will be described briefly.
꾸지뽕(Cudrania tricuspidata)은 쌍떡잎식물 쐐기풀목 뽕나무과의 낙엽활엽 소교목에 속하는 식물로 굿가시나무라고도 한다. 꾸지뽕은 한국, 중국 및 일본에서 주로 항암, 항염증, 위염 및 간손상에 중요한 전통 생약제로 사용되고 있으며 또한 꾸지뽕에는 β-sitosterol, β-sitosterol glucoside, artocapesin, norartocapesin, 5-O-methylgenistein, phytoalexins 등이 함유되어 있어 최근 혈당과 체중을 조절할 수 있는 식품으로 사용되고 있다.Cudrania tricuspidata (Cudrania tricuspidata) is a deciduous broad-leaved arboreous tree of the dicotyledonous plant Nettlesia spp. CJ is used as a traditional herbal medicine in Korea, China and Japan, which is important for anti-cancer, anti-inflammatory, gastritis and liver damage. In addition, β-sitosterol, β-sitosterol glucoside, artocapesin, norartocapesin, 5-O-methylgenistein and phytoalexins Has recently been used as a food that can control blood sugar and body weight.
실험예Experimental Example 2. 2. 돼지감자여주즙이Pork potato juice 인슐린에 미치는 효과 Effect on insulin
(2-1) 실험방법(2-1) Experimental method
상기 실험예 1의 1)~4)와 같은 방법으로 실험한다.Experiments are carried out in the same manner as in 1) to 4) of Experimental Example 1 above.
5) 인슐린 측정은 4주간 사육 후 희생시켜 심장에서 채혈하여 3000rpm에서 15분간 원심분리하여 혈청 인슈린을 Insulin ELISA kit(shibayagi, Japan)로 측정하였다.5) Insulin was measured by insulin ELISA kit (shibayagi, Japan) after blood collection for 4 weeks. The insulin was collected from the heart and centrifuged at 3000 rpm for 15 minutes.
(2-2) 실험결과(2-2) Experimental results
실험결과는 표 4 및 첨부된 도면의 도 2를 참조한다. The experimental results refer to Table 4 and Figure 2 of the accompanying drawings.
표 4 및 도 2는 돼지감자여주즙이 인슐린에 미치는 효과를 측정한 결과를 나타낸 것으로, 정상군의 혈청 인슐린은 4.03±0.52ng/mL, STZ군은 2.92±0.61ng/mL, 돼지감자즙군은 3.12±0.40ng/mL, 돼지감자즙여주즙군 3.41±0.29ng/mL로 STZ투여군은 정상군에 비하여 인슐린 함량이 유의적으로 낮았고, STZ투여군 중에서는 돼지감자여주혼합즙(HT2)의 혈청 인슐린 함량이 유의적으로 높음을 알 수 있었다.Table 4 and FIG. 2 show the results of measuring the effect of porcine potato juice on insulin. Serum insulin was 4.03 ± 0.52 ng / mL in the normal group, 2.92 ± 0.61 ng / mL in the STZ group, 3.12 ± 0.40 ng / mL, and 3.41 ± 0.29 ng / mL in the potato juice juice group. In the STZ group, the insulin content was significantly lower than that of the normal group. Serum insulin content of the potato juice mixture (HT2) Which was significantly higher than that of the control group.
이하에서, 본 발명에 사용된 수세미에 대해 간략히 서술한다.Hereinafter, the scrubber used in the present invention will be briefly described.
수세미(Sponge gourd)는 박과(Cucurbitaceae)에 속하는 1년생 덩굴 식물로서 수세미오이라고도 한다. 지금까지 밝혀진 수세미 성분으로는, 각종 세포에 영양소를 공급하며 삼투압을 조절하는 회분, 열을 내리고 해독작용을 하는 카로틴, 면역작용과 혈액의 생성 및 정혈작용을 하는 단백질이 포함되어 있다. Sponge gourd is a perennial vine plant belonging to the genus Cucurbitaceae. Soil ingredients that have been found up to now include aspirates that control nutrients in various cells and regulate osmotic pressure, carotene that reduces heat and detoxifies, and proteins that produce immune and blood and blood.
이상에서 상술한 바와 같이, 본 발명에 따른 생돼지감자 1kg당 0.25% 건조여주함유즙을 25% 함유한 물을 음용한 군에서 혈당강하 및 인슐린 분비를 촉진하는 효과가 있음을 확인하였다.As described above, it was confirmed that the effect of promoting blood glucose lowering and insulin secretion in the group of drinking water containing 0.25% dry yeast-containing juice by 25% per 1 kg of raw porcine potato according to the present invention was confirmed.
따라서, 본 발명에 따른 돼지감자여주즙은 혈당강하 및 당뇨병을 개선하는 음료, 차, 죽 및 과자 조성물 등에 다양하게 이용될 수 있을 것으로 기대된다. Therefore, it is expected that the porcine potato juice according to the present invention can be variously used for beverage, tea, porridge, and cookie composition which improves blood glucose lowering and diabetes.
Claims (2)
미성숙한 초록색의 여주열매(생여주) 1kg을 깨끗이 씻고 얇게 썰어 50~60℃에서 6~8시간 건조하여 생여주 1000g당 95~105g의 건조여주를 얻는단계; 및
생돼지감자 1000g당 건조여주 2.5g을 혼합하여 소량의 물을 가하고 고압으로 105~115℃에서 2~3시간 처리하는 단계를 포함하는 돼지감자여주즙 제조방법.
Washing 1kg of mature raw pork potatoes to remove the moisture:
1kg of immature green lily of the valley (lye) is cleanly washed, thinly sliced and dried at 50 ~ 60 ° C for 6 ~ 8 hours to obtain 95 ~ 105g of dry lye per 1000g of lard; And
Which comprises mixing 2.5 g of dry yeast per 1000 g of raw pork potato, adding a small amount of water, and treating the mixture at 105 to 115 캜 for 2 to 3 hours under high pressure.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160052735A KR20170123439A (en) | 2016-04-29 | 2016-04-29 | The method for manufacturing a juice containing jerusalem artichoke and bitter melon, and juice manufactured by the method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160052735A KR20170123439A (en) | 2016-04-29 | 2016-04-29 | The method for manufacturing a juice containing jerusalem artichoke and bitter melon, and juice manufactured by the method |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20170123439A true KR20170123439A (en) | 2017-11-08 |
Family
ID=60385472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160052735A KR20170123439A (en) | 2016-04-29 | 2016-04-29 | The method for manufacturing a juice containing jerusalem artichoke and bitter melon, and juice manufactured by the method |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20170123439A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210050034A (en) * | 2019-10-25 | 2021-05-07 | 농업회사법인 주식회사 장수식품 | A composition for improving, preventing and treating of diabetes mellitus |
KR20220051936A (en) * | 2020-10-20 | 2022-04-27 | 충청북도 (관리부서:충청북도 농업기술원) | Manufacturing method of functional peach jelly |
-
2016
- 2016-04-29 KR KR1020160052735A patent/KR20170123439A/en active Search and Examination
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210050034A (en) * | 2019-10-25 | 2021-05-07 | 농업회사법인 주식회사 장수식품 | A composition for improving, preventing and treating of diabetes mellitus |
KR20220051936A (en) * | 2020-10-20 | 2022-04-27 | 충청북도 (관리부서:충청북도 농업기술원) | Manufacturing method of functional peach jelly |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101200344B1 (en) | Manufacturing method of functional Momordica charantia tea for lowering blood glucose | |
US6416795B1 (en) | Herbal extract composition for stress prevention and treatment | |
KR102180204B1 (en) | Manufacturing method of Kimchi for preventing diabetes and alcohol-based liver damage | |
KR101686898B1 (en) | Food composition for preventing and improving diabetes using Momordica charantia, Corni fructus | |
KR101312491B1 (en) | Manufacturing method of functional Momordica charantia beverage for lowering blood glucose | |
KR20160017223A (en) | Composition for muscle development and muscle fatigue recovery comprising Angelica keiskei extract and Red ginseng extract as active ingradients | |
KR20160144791A (en) | Composition for relieving menopausal symptom | |
KR101261029B1 (en) | Composition for preventing or improving the diabete containing suaeda japonica | |
CN106359734A (en) | Sugar-free tea drink with weight-losing function and making method thereof | |
KR20170123439A (en) | The method for manufacturing a juice containing jerusalem artichoke and bitter melon, and juice manufactured by the method | |
US10799547B2 (en) | Composition comprising suaeda japonica for preventing or alleviating diabetes | |
CN105011286A (en) | Balsam pear maca functional drink | |
CN107495020A (en) | A kind of suitable polypeptide beverage water of diabetic population and its preparation technology | |
US20080311252A1 (en) | Chocolate based dietary supplement product or sweet beverage product | |
KR20200079206A (en) | Composition comprising an extract of Senna obtusifolia for preventing or treating diabetes mellitus | |
KR101952643B1 (en) | Preparation method of grain noodle | |
KR101536974B1 (en) | Composition for preventing and improving diabetes comprising extracts of Momordica charantia, Corni fructus, Schizandra chinensis and Jujube | |
KR102368446B1 (en) | Composition for preventing or treating diabetes | |
KR102292059B1 (en) | Composition comprising of the extract of Cissus verticillata and Cyclopia Intermedia as an active ingredient for preventing or treating diabetic complication and diabetes | |
KR101692604B1 (en) | Composition comprising pomegranate juice extrated low speeed for improving liver function | |
CN106421491A (en) | Formula of radix helicteris oral liquid with blood glucose reducing effect and preparation method | |
KR101934116B1 (en) | A composition comprising the extract of chives, helianthus tuberosus and red ginseng for liver protection | |
KR100496119B1 (en) | Drink manufacture method for containing helianthus tuberosus and herb | |
CN104304487A (en) | Health milk with efficacy of decreasing blood sugar and preparation method of health milk | |
KR101976710B1 (en) | Composition for prevention, improvement or treatment of diabetes with extracts from Gynura procumbens leaf, Cornus officinalis and Pyrus ussuriensis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment |